--- title: "Intensity Therapeutics (INTS) news: reverse split and delisting" url: "https://aibio.space/companies/intensity-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "INTS reverse split, delisting, offering and Nasdaq notice news: Intensity Therapeutics gets second 180 days to meet Nasdaq minimum bid price requirement." --- INTS Intensity Therapeutics, Inc. NASDAQ · United States # Intensity Therapeutics (INTS) news INTS reverse split, delisting and offering news Company Updates · 2026-08-11 ## [Intensity Therapeutics reports Q2 2026 results and trial updates](https://aibio.space/news/intensity-therapeutics-reports-q2-2026-results-trial-updates/) Cash and cash equivalents were $9.5 million at June 30, 2026. The company began activities to resume enrollment in its INVINCIBLE-3 study and restarted treatment in INVINCIBLE-4. ## Latest Intensity Therapeutics news 1. 2026-05-07 Company Updates [Intensity Therapeutics reports Q1 2026 results and enrollment plans](https://aibio.space/news/intensity-therapeutics-reports-q1-2026-results-enrollment-plans/) Cash and cash equivalents were $10.2 million at March 31, 2026. The company plans to resume enrollment in INVINCIBLE-3 at a limited number of U.S. sites by the third quarter of 2026. 2. 2025-12-05 Listings [Intensity Therapeutics gets second 180 days to meet Nasdaq minimum bid price requirement](https://aibio.space/news/intensity-therapeutics-gets-second-180-days-meet-nasdaq-minimum-bid/) Nasdaq gave Intensity until June 1, 2026 to restore a $1.00 closing bid price. The company says it may use a reverse stock split, and the notice has no immediate effect on its listing. 3. 2025-08-12 Listings [Intensity Therapeutics regains Nasdaq stockholders' equity compliance](https://aibio.space/news/intensity-therapeutics-regains-nasdaq-stockholders-equity-compliance/) Nasdaq said on August 8, 2025 that Intensity meets the $2,500,000 stockholders' equity requirement. That finding rests partly on share sales made in July, and the company could still face delisting if its next periodic report does not show compliance. 4. 2025-08-04 Financings [Intensity Therapeutics raises $6.6 million from July 2025 at-the-market sales](https://aibio.space/news/intensity-therapeutics-raises-6-6-million-july-2025-market-sales/) Intensity sold 19,868,658 shares at an average of $0.3323 each under its at-the-market program in July 2025. The company says its cash now reaches into the second half of 2026, but the release gives no cash balance. 5. 2025-05-20 Listings [Intensity Therapeutics gets Nasdaq stockholders' equity deficiency notice](https://aibio.space/news/intensity-therapeutics-gets-nasdaq-stockholders-equity-deficiency/) Nasdaq says the company, whose cash was $2,590 thousand at year-end 2024, fell short of the $2,500,000 stockholders' equity minimum and has until July 3, 2025 to submit a compliance plan. ## Intensity Therapeutics at a glance - **Ticker**: INTS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $9.5 million ### Related companies - [Iovance Biotherapeutics](https://aibio.space/companies/iovance-biotherapeutics/) NASDAQ: IOVA - [Mosaic ImmunoEngineering](https://aibio.space/companies/mosaic-immunoengineering/) OTC: CPMV - [Dyne Therapeutics](https://aibio.space/companies/dyne-therapeutics/) NASDAQ: DYN - [Relay Therapeutics](https://aibio.space/companies/relay-therapeutics/) NASDAQ: RLAY - [Prelude Therapeutics](https://aibio.space/companies/prelude-therapeutics/) NASDAQ: PRLD - [MiNK Therapeutics](https://aibio.space/companies/mink-therapeutics/) NASDAQ: INKT - [Enzolytics](https://aibio.space/companies/enzolytics/) OTC: ENZC - [TScan Therapeutics](https://aibio.space/companies/tscan-therapeutics/) NASDAQ: TCRX ### Also on NASDAQ - [Benitec Biopharma](https://aibio.space/companies/benitec-biopharma/) BNTC - [BriaCell Therapeutics](https://aibio.space/companies/briacell-therapeutics-bctx/) BCTX - [LeonaBio](https://aibio.space/companies/leonabio/) LONA - [Bluejay Diagnostics](https://aibio.space/companies/bluejay-diagnostics/) BJDX - [Twist Bioscience](https://aibio.space/companies/twist-bioscience/) TWST - [Prime Medicine](https://aibio.space/companies/prime-medicine/) PRME ## What Intensity Therapeutics does Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on localized cancer reduction through direct injection of its product candidates into tumors. Its DfuseRx discovery platform creates anti-cancer product candidates that combine active agents with amphiphilic molecules, which allow the drugs to disperse through a tumor and diffuse into cancer cells. Its lead candidate, INT230-6, combines cisplatin, vinblastine sulfate and an amphiphilic molecule called SHAO in one vial at a fixed ratio. The Phase 3 INVINCIBLE-3 study tests INT230-6 as a monotherapy against standard-of-care drugs in second- and third-line treatment of certain soft tissue sarcoma subtypes, with overall survival as the endpoint. The study is a 333-patient trial. New site activations and enrollment were paused in March 2025 because of funding constraints. The Phase 2 INVINCIBLE-4 study, run with the Swiss Cancer Group, tests INT230-6 in localized triple-negative breast cancer. Full approval to resume enrollment was granted on March 26, 2026, with resumption planned for the second quarter of 2026. The company is targeting completion of enrollment by the end of 2027. | Product or program | What it is | Stage | |---|---|---| | INT230-6 | Intratumoral combination of cisplatin, vinblastine sulfate and SHAO | Phase 3 INVINCIBLE-3 (enrollment paused); Phase 2 INVINCIBLE-4 | Summarised from the company's [10-K filed Mar 27, 2026](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000024/intensity-20251231.htm). ## Intensity Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$6.8 million](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000024/) | [$10.5 million](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000024/) | | Net income (loss) | [-$11.6 million](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000024/) | [-$16.3 million](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000024/) | | Cash from operations | [-$9.2 million](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000024/) | [-$15.2 million](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000024/) | | Cash and equivalents | [$11.9 million](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000059/) | [$2.6 million](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000024/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $9.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Intensity Therapeutics Did Intensity Therapeutics do a reverse stock split? Our latest story on this, dated Dec 5, 2025: "Intensity Therapeutics gets second 180 days to meet Nasdaq minimum bid price requirement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/intensity-therapeutics-gets-second-180-days-meet-nasdaq-minimum-bid/). Was Intensity Therapeutics delisted? Our latest story on this, dated Aug 12, 2025: "Intensity Therapeutics regains Nasdaq stockholders' equity compliance". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/intensity-therapeutics-regains-nasdaq-stockholders-equity-compliance/). Has Intensity Therapeutics raised money recently? Our latest story on this, dated Aug 4, 2025: "Intensity Therapeutics raises $6.6 million from July 2025 at-the-market sales". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/intensity-therapeutics-raises-6-6-million-july-2025-market-sales/). Has Intensity Therapeutics received a Nasdaq deficiency notice? Our latest story on this, dated May 20, 2025: "Intensity Therapeutics gets Nasdaq stockholders' equity deficiency notice". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/intensity-therapeutics-gets-nasdaq-stockholders-equity-deficiency/). What is the ticker symbol of Intensity Therapeutics? Intensity Therapeutics, Inc. trades under the ticker INTS on NASDAQ. Where is Intensity Therapeutics listed? Intensity Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Intensity Therapeutics? The SEC Central Index Key (CIK) for Intensity Therapeutics, Inc. is 1567264. Its filings are on SEC EDGAR. How many shares does Intensity Therapeutics have outstanding? 3,264,879 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Intensity Therapeutics listed under? Our directory records Intensity Therapeutics, Inc. under United States. What does Intensity Therapeutics do? Our directory classifies Intensity Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Intensity Therapeutics? The ISIN recorded for Intensity Therapeutics, Inc. is US45828J2024. Does aibio.space cover Intensity Therapeutics? aibio.space lists Intensity Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Intensity Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Intensity Therapeutics develop? Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on localized cancer reduction through direct injection of its product candidates into tumors. Its DfuseRx discovery platform creates anti-cancer product candidates that combine active agents with amphiphilic molecules, which allow the drugs to disperse through a tumor and diffuse into cancer cells. What is INT230-6 from Intensity Therapeutics? INT230-6: Intratumoral combination of cisplatin, vinblastine sulfate and SHAO Stage: Phase 3 INVINCIBLE-3 (enrollment paused); Phase 2 INVINCIBLE-4. ## Investor discussion: Intensity Therapeutics Members talk about Intensity Therapeutics (INTS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Intensity Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-03-23 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000020/intensity-424b5prosuppatmi.htm) 2. 2026-03-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000014/ints20260305ex99120260306n.htm) 3. 2026-02-13 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000007/ints20260213ex991reversest.htm) 4. 2025-12-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1567264/000156726425000111/ints20251208ex99120251205n.htm) 5. 2025-12-04 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1567264/000156726425000108/intensity-424b5prosuppatmi.htm) 6. 2025-10-23 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1567264/000156726425000096/intensity-20251022.htm) 7. 2025-09-09 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1567264/000156726425000090/intensity-20250904.htm) 8. 2025-08-28 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1567264/000156726425000087/intensity-20250828.htm) 9. 2025-08-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1567264/000156726425000081/intensity-20250808.htm) 10. 2025-08-04 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1567264/000156726425000071/ints20250804ex991july2025a.htm) 11. 2025-06-11 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1567264/000162828025030702/intensity-prosuppxfurthera.htm) 12. 2025-06-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1567264/000156726425000056/intensity-20250606.htm) 13. 2025-05-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1567264/000156726425000042/intensity-20250519.htm) 14. 2025-04-22 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1567264/000162828025018892/intensity-sx1.htm) 15. 2024-11-20 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1567264/000162828024048703/ints-prospectussupplementa.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:INTS on TradingView](https://www.tradingview.com/symbols/NASDAQ-INTS/). ## SEC filings and registration - **SEC name**: Intensity Therapeutics, Inc. - **CIK**: 1567264 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: INTS (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 1 ENTERPRISE DRIVE, SUITE 430, SHELTON, CT, 06484 - **Phone**: 203-221-7381 - **Shares outstanding**: 3,264,879 as of 2026-08-07 (10-Q filed 2026-08-11) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000061/intensity-20260811.htm) filed 2026-08-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000059/intensity-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000049/intensity-20260616.htm) filed 2026-06-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000047/intensity-20260507.htm) filed 2026-05-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000046/intensity-20260331.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000035/intensity-20260430.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000025/intensity-20260327.htm) filed 2026-03-27 - [10-K](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000024/intensity-20251231.htm) filed 2026-03-27 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001567264), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Intensity Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker INTS, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Intensity Therapeutics, Inc. - **Ticker**: INTS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US45828J2024 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-INTS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/intensity-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Intensity Therapeutics (INTS) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/intensity-therapeutics/